<DOC>
	<DOC>NCT01814761</DOC>
	<brief_summary>This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (IOP).</brief_summary>
	<brief_title>A Study of Bimatoprost 0.01% in the Clinical Setting</brief_title>
	<detailed_description />
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Bimatoprost</mesh_term>
	<criteria>Diagnosis of primary openangle glaucoma or ocular hypertension Determined by the treating physician to require treatment with bimatoprost 0.01%. Previous use of Lumigan® 0.01%</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>